載入中
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
前收盤價
US$1.08
+US$0.01 · +0.93%
盤中時間採用ET。市場資料可能有所延遲。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日內區間
目前US$1.08
52週區間
目前US$1.08
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
44
合理估值
情緒
58
多空交錯
風險
72
高風險
動能
21
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
日內區間
目前US$1.08
52週區間
目前US$1.08
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | — | — | 50萬 USD | 50萬 USD |
| 毛利 | — | — | — | 50萬 USD | 50萬 USD |
| 研究與開發 | 778.07萬 USD | 1163.94萬 USD | 1128.77萬 USD | 1173.37萬 USD | 1061.93萬 USD |
| 銷售、一般及管理費用 | 687萬 USD | 749.3萬 USD | 974.27萬 USD | 1368.79萬 USD | 1088.79萬 USD |
| 營業費用 | 1465.07萬 USD | 1913.24萬 USD | 2103.04萬 USD | 2542.16萬 USD | 2150.72萬 USD |
| 利息收入 | 15.57萬 USD | 45.02萬 USD | 72.58萬 USD | 50.26萬 USD | 1.81萬 USD |
| 利息支出 | — | — | 19.71萬 USD | 502.86萬 USD | 56.99萬 USD |
| 折舊和攤銷 | 69.89萬 USD | 71.81萬 USD | 72萬 USD | 73.16萬 USD | 70.29萬 USD |
| 營業利益 | −1465.07萬 USD | −1913.24萬 USD | −2103.04萬 USD | −2492.16萬 USD | −2100.72萬 USD |
| 淨利 | −1449.5萬 USD | −1862.02萬 USD | −1951.5萬 USD | −3589.82萬 USD | −2076.93萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$10.00
上漲空間 825.93%| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2025年7月25日 | 1:15 | — | — |
股票分割 | 2022年3月1日 | 1:15 | — | — |
股票分割 | 2017年5月30日 | 1:14 | — | — |
股票分割 | 2013年10月29日 | 111:500 | — | — |
股票分割 | 2006年2月28日 | 1:15 | — | — |
已生效 2025年7月25日
1:15
已生效 2022年3月1日
1:15
已生效 2017年5月30日
1:14
已生效 2013年10月29日
111:500
已生效 2006年2月28日
1:15
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
